

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>6</sup>:</b> <b>A61K 31/53, 9/14, 9/19</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 97/00681</b> <b>(43) International Publication Date:</b> 9 January 1997 (09.01.97)
<b>(21) International Application Number:</b> PCT/EP96/02759 <b>(22) International Filing Date:</b> 20 June 1996 (20.06.96) <b>(30) Priority Data:</b> 9512854.2 23 June 1995 (23.06.95) GB <b>(71) Applicant (for all designated States except US):</b> THE WELL-COME FOUNDATION LIMITED [GB/GB]; Glaxo Wellcome House, Berkeley Avenue, Greenford, Middlesex UB6 0NN (GB). <b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only):</b> FLOYD, Alison, Green [US/US]; Glaxo Wellcome Inc., Five Moore Drive, Research Triangle Park, NC 27709 (US). JAIN, Sunil [IN/US]; Glaxo Wellcome Inc., Five Moore Drive, Research Triangle Park, NC 27709 (US). <b>(74) Agent:</b> GALLAFENT, Alison; Glaxo Wellcome plc, Glaxo Wellcome House, Berkeley Avenue, Greenford, Middlesex UB6 0NN (GB).		<b>(81) Designated States:</b> AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>With international search report.</i>
<b>(54) Title:</b> PHARMACEUTICAL COMPOSITION CONTAINING LAMOTRIGINE  <b>(57) Abstract</b>  A lyophilized formulation of lamotrigine having been prepared by lyophilizing a frozen sterile aqueous solution of lamotrigine mesylate in which the pH is from 2.5 to 4.		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

## PHARMACEUTICAL COMPOSITION CONTAINING LAMOTRIGINE

The present invention relates to a novel pharmaceutical formulation of lamotrigine, a process for its preparation, and its use in medical therapy.

Status Epilepticus (SE) is a life-threatening condition in which the high morbidity and mortality rates are directly related to the duration of seizure activity. There exists a clinical need for an antiepileptic drug (AED) that may be administered rapidly and safely via the intravenous route to achieve therapeutic plasma concentrations for the treatment of SE. The only AED currently available in an intravenous formulation is phenytoin. However, recommended doses must be administered over a period of at least 20 minutes to avoid cardiovascular side-effects (including tachycardia, bradycardia, hypotension and cardiac arrhythmias) produced by the drug and its solvent, propylene glycol. Furthermore, intravenous phenytoin administration is commonly associated with injection site reactions including pain, inflammation and sclerosis.

A clinical need for an intravenous AED additionally exists for patients who are unable to swallow an oral formulation for a variety of reasons including unconsciousness (post-ictal or secondary to acute trauma), anesthesia during surgery and post-operative recovery and the presence of an intra-tracheal tube for the facilitation of mechanical ventilation.

Lamotrigine may be chemically named 3,5-diamino-6-(2,3-dichlorophenyl)-1,2,4-triazine and is disclosed in European patent 21121 and US patent 4602017. It is useful in the treatment of SE and is commercially available under the trade name "Lamictal" as an oral tablet formulation. Typically, a therapeutic dose of lamotrigine for an adult human being comprises a loading dose of, say, 1000-1500 mg followed by a maintenance dose of, say, 500-700 mg/day. Plasma concentrations of lamotrigine of about 2-4  $\mu\text{g/mL}$  are generally effective in controlling SE for add-on therapy, i.e. when taken concomitantly with other AEDs. Plasma concentrations of about 8-10  $\mu\text{g/mL}$  are generally effective for monotherapy.

The clinical management of SE with lamotrigine would be assisted by the availability of formulations in addition to tablet formulations. In particular, as indicated above, an injectable formulation of lamotrigine would be of advantage in initiating treatment intravenously so as to obtain the required plasma concentrations and bioavailability as rapidly as possible. It would also find utility in an emergency room situation in which patients are already experiencing convulsions and are not able to take the tablet form.

The need for an injectable formulation of lamotrigine has already been recognised. Initially, its development was hampered by the poor solubility of the base form of the drug. The aqueous solubility of lamotrigine is only 0.17 mg/mL at about room temperature and does not significantly vary with pH (Table I).

Table I - Solubility of Lamotrigine

Aqueous Medium	Amount Dissolved (mg/mL)
Water at 25°C	0.17
Water at 37°C	0.57
HCl (pH 1.2) at 37°C	0.46
Phosphate buffer (pH 6.0) at 37°C	0.68
Phosphate buffer (pH 7.5) at 37°C	0.56
0.01N Sodium hydroxide at 25°C	0.30

Consequently, the sparingly soluble nature of lamotrigine base in water would necessitate the administration of an undesirably large volume of solution to provide a therapeutic dose.

European patent 247892 and US patent 4847249 disclose the isethionate (2-hydroxyethanesulphonate) salt of lamotrigine and its use in the provision of an injectable formulation. The isethionate salt has an aqueous solubility of 404 mg/mL at about room

temperature which is substantially higher than that of the free base. It therefore enables the administration of a therapeutic dose to a patient in a much more acceptable volume of solution. However, isethionic acid is unstable if it is not prepared in situ and tends to degrade leading to uncharacterised by-products and potential regulatory complications. In situ preparation avoids this problem but is itself a cost-inefficient method for producing the isethionate salt.

Further development of an injectable formulation has been hampered by the instability of lamotrigine itself in aqueous media. In particular, lamotrigine is hydrolytically decomposed to 3-amino-5-keto-6-(2,3-dichlorophenyl)-1,2,4-triazine and 3,5-diketo-6-(2,3-dichlorophenyl)-1,2,4-triazine. Moreover, the hydrolysis is catalysed under acidic conditions. Such instability of the active ingredient is clearly undesirable for an injectable formulation for which an acceptable shelf life is a particular requirement.

An injectable formulation of lamotrigine has now been developed. The formulation is in lyophilized form and utilises the mesylate salt (that is the methanesulphonate salt) of lamotrigine. It is prepared from an aqueous solution having a pH of from 2.5 to 4. The formulation is stable in that no significant hydrolysis of the active ingredient occurs on storage. In addition, methanesulphonic acid itself is stable and, unlike isethionic acid, does not need to be prepared in situ resulting in a more efficient production process. The lyophilized formulation may also be reconstituted to provide an acceptable volume of solution containing a therapeutic dose of lamotrigine for administration to patients.

The present invention provides a lyophilized injectable formulation of lamotrigine that has been prepared by lyophilizing a substantially frozen sterile aqueous solution of lamotrigine mesylate having a pH of from 2.5 to 5, preferably 2.5 to 4.

According to a further aspect of the present invention, there is provided a lyophilized formulation containing lamotrigine mesylate present in an amount of 100 to 1000mg, calculated as the free base.

Preferably, there is provided by the present invention, a lyophilized formulation containing lamotrigine mesylate present in an amount of 250-1000mg, calculated as the free base, and more preferably present in an amount of substantially 250mg, calculated as the free base.

Lamotrigine mesylate is a known salt of lamotrigine. It is disclosed in European patent 247892 and US patent 4847249 as an intermediate in the preparation of the isethionate salt. Its aqueous solubility is 63 mg/mL at about room temperature which is significantly higher than that of the lamotrigine base. The mesylate salt is particularly amenable to the provision of a stable, lyophilised form of lamotrigine that can simply be reconstituted to obtain an injectable formulation for use in the treatment of SE.

Advantageously a lyophilized formulation according to the present invention further comprises at least one bulking agent selected from the group consisting of mannitol, dextrose, lactose, sucrose, sorbitol, and glycine, in particular mannitol. Suitably, the bulking agent is present in a lyophilized formulation according to the present invention in an amount of 192-470mg.

There is still further provided by the present invention a process of preparing a lyophilized formulation substantially as hereinbefore described, which process comprises lyophilizing a substantially frozen sterile aqueous solution of lamotrigine mesylate in which the pH is from 2.5 to 5, preferably 2.5 to 4.

Typically, the concentration of lamotrigine, calculated as the free base, prior to lyophilization and which is employed in the preparation of a lyophilized formulation according to the present invention is preferably from 1 to 60 mg/mL, more preferably from 20 to 30mg/mL, for example 25mg/mL.

The mesylate salt is conveniently produced in situ by adding lamotrigine powder to an aqueous solution of methanesulphonic acid optionally containing at least one bulking agent selected from

the group consisting of mannitol, dextrose, lactose, sucrose, sorbitol and glycine, preferably mannitol. Preferably, the methanesulphonic acid is present in an amount that is substantially equimolar with or greater than the amount of lamotrigine base.

The pH of the aqueous solution of lamotrigine employed in lyophilization is preferably from 2.8 to 3.5, more preferably from 3.3 to 3.5. Appropriate adjustment of the pH can be made with an aqueous solution of either methanesulphonic acid itself or sodium hydroxide.

Although one or more pharmaceutically acceptable cosolvents may be used in addition to water, it is preferred that the solution is wholly or substantially aqueous.

The aqueous solution of lamotrigine mesylate may be sterilised conventionally, for example, by filter sterilisation. It may then be dispensed into sterile, plastic or glass containers, such as ampoules or vials, in volumes of, for example, from 7 to 10mL. The aqueous solution may be frozen at a temperature of from -10° to -24° C. The substantially frozen aqueous solution may then be maintained at this temperature until lyophilization is commenced.

Lyophilisation of the substantially frozen aqueous solution may be carried out conventionally involving, for example, both primary drying and secondary drying. Primary drying may be carried out via sublimation by using controlled application of vacuum and heat, for example under a substantial vacuum of about 0.1 to 0.5 Torr for sufficient time to effect removal of substantially all the frozen water and/or other solvent. Secondary drying is preferably carried out subsequently under a substantially similar vacuum to remove as much as possible of the last traces of adsorbed water or other solvent, thus providing a dry cake or powder.

The temperature at which primary drying is carried out ranges from -10° to 0° C at the beginning of the process so as to maintain the solution in a substantially or completely frozen form. As the process proceeds and the product temperature reaches the desired shelf temperature, the primary drying phase is completed. The temperature at which secondary drying is carried out ranges from

25 to 35°C in order to remove any adsorbed water and/or other solvent. The moisture content of the resulting cake or powder is preferably less than 2.5% by weight. Once the lyophilisation has been completed, the sterile, plastic or glass container containing the lyophilised formulation may then be stoppered or sealed.

The resulting lyophilized formulation is physically and chemically stable at room temperature and under accelerated storage conditions.

The lyophilised product may be reconstituted with a sterile carrier suitable for intravenous administration, such as sterile water or 5% aqueous dextrose solution and diluted as required, say, to 1 to 15mg lamotrigine per mL with the sterile carrier. Reconstitution with water to the appropriate concentration of lamotrigine provides an isotonic solution and further dilution with 5% aqueous dextrose injection does not cause any appreciable change in the tonicity of the formulation. The reconstituted and/or diluted solution is physically and chemically stable when stored at room temperature for 24 hours, and provides an injectable formulation of lamotrigine suitable for intravenous administration.

There is therefore further provided by the present invention an injectable formulation containing lamotrigine mesylate, wherein the concentration of lamotrigine mesylate is in the range of 1 to 60mg/ml calculated as the free base. Suitably, the formulation is prepared by reconstitution of a lyophilized formulation substantially as hereinbefore described with a sterile carrier suitable for intravenous administration.

Aptly, the lamotrigine mesylate concentration in the injectable formulation is in the range of 1 to 50mg/ml, more aptly 1 to 20mg/ml, such as 1 to 15mg/ml or substantially 20mg/ml.

The invention therefore further provides use of a lyophilized formulation substantially as hereinbefore described, in the manufacture of an injectable formulation containing lamotrigine, and still further a process of preparing an injectable formulation comprising reconstituting a

lyophilized formulation substantially as hereinbefore described with a sterile carrier suitable for intravenous administration.

To avoid undesirable side effects, a reconstituted injectable solution of lamotrigine according to the present invention is preferably isotonic with the blood serum of the patient. An isotonic injectable solution may be obtained by including at least one bulking agent that increases the tonicity of the solution to the required level. Conveniently, the bulking agent is included in the aqueous solution prior to lyophilisation. Suitably the bulking agent is selected from the group consisting of mannitol, dextrose, lactose, sucrose, sorbitol and glycine, in particular mannitol, and is aptly present in an injectable formulation according to the present invention at a concentration in the range of 12 to 47 mg/ml. Saline is not a useful agent in this regard since it may lead to the formation of the hydrochloride salt of lamotrigine which is not very soluble and may result in the formation of a precipitate. The amount of the agent included in the aqueous solution will vary from agent to agent. In the case of mannitol, the amount is preferably from 370 to 470 mg per vial, prior to lyophilisation. Mannitol is particularly useful in that it also has good cake-forming properties.

The reconstituted solution normally has a pH of from 2.5 to 5, preferably 3.4 to 4. The use of such an acidic injectable solution of lamotrigine does not present any significant adverse physiological effect on administration to the patient. It would seem that the pH of the solution is raised to neutral almost as soon as contact is made with the bloodstream, the lamotrigine being rapidly distributed within the bloodstream. It is preferred that this process is not impeded in any way and that therefore neither the freeze-dried formulation nor the injectable solution contains a buffering agent, at least not a strong buffering agent.

The amount of lamotrigine in each vial may vary from 250 to 1000 mg calculated as the base.

Generally from 5 to 10 mg per kg bodyweight of lamotrigine mesylate is intravenously administered per kg bodyweight to patients to provide a therapeutically effective dose for the treatment of SE. The rate of administration of the reconstituted solution providing the required dose may vary.

The present invention further provides a method of treating a patient with epilepsy, which method comprises intravenously administering to the patient an injectable formulation containing lamotrigine substantially as hereinbefore described.

The following examples are provided to assist in the practise of and further illustrate the present invention, and should not however be used to limit the scope of the invention.

- 1 Mannitol is dissolved in appropriate amount of water. The amount of mannitol needed is calculated to provide tonicity upon reconstitution and may range from 377.85 to 465.5 mg per vial.
2. The mesylate salt of lamotrigine is formed in situ during the manufacturing process described in European patent 21121 and US patent 4486354 by addition of commercially available methanesulfonic acid. Preferably the molar ratio of 3,5-diamino-6-(2,3-dichlorophenyl)-1,2,4-triazine to the acid is approximately 1:1 or higher.
3. When the appropriate amounts of lamotrigine and methanesulfonic acid are combined, the resulting solution pH ranges from approximately 2.8 to 3.5.
4. The solution pH may be adjusted to a range 3.3-3.5 with sodium hydroxide solution or methanesulfonic acid solution.
5. The final concentration of the lamotrigine calculated as free base in solution prior to freeze drying may vary from 1-50 mg per mL, preferably 25 mg per mL.

6. The solution is chemically and physically stable at room temperature for a period of at least 7 days and may be held in suitable stainless steel/glass manufacturing tank for this period of time, if needed.
7. The solution is then sterile filtered and filled in appropriate vials preferably to a fill volume of 10 g.
8. The vials are then loaded into a freeze drier which is precooled to 5°C prior to loading.
9. The solution is then frozen to -24°C for 4-5 hours. Primary drying is initiated by ramping the shelf temperature to 0°C while maintaining the vacuum at 0.5 Torr. After the product temperature reaches the shelf temperature, secondary drying is initiated and conducted at a product temperature of 35°C for 6-8 hours. The chamber pressure is maintained at 0.5 Torr during lyophilisation.
10. The stability profile of the lyophilized formulation was assessed under stressed and room temperature storage conditions. The resulting data are set forth in Table 2 from which it is evident that the formulation demonstrates physico-chemical stability on storage for 6 months under stressed conditions (40°C/75% RH). No loss in potency and no significant decomposition was observed under these conditions.
11. Reconstitution of the lyophilized formulation with 12.5 mL of sterile water for injection provides an isotonic solution containing 20 mg lamotrigine free base per mL.
12. The stability of the reconstituted product was also assessed. The resulting data are set forth in Tables 3 and 4 from which it is evident that the reconstituted solution is physically and chemically stable when stored at room temperature for a period of at least 3 days.

13. The reconstituted solution can be delivered as is or can be further diluted to 1 to 15 mg lamotrigine per mL. The diluted solution (i.e. 5% dextrose) is chemically and physically stable up to 48 hours at 5 and 25°C. Antimicrobial effectiveness of the product diluted with 5% dextrose is demonstrated for 24 and 48 hours on storage at 25 and 5°C, respectively.

In the above protocol, examples of specific values of lamotrigine, mannitol and methanesulphonic acid that have been employed are as follows.

Ingredient	Amount per vial(mg)
lamotrigine	250.0
mannitol	377.8
methanesulphonic acid	93.75.

Further methanesulphonic acid, sodium hydroxide and water were added to achieve the required pH and volumes as given in the above protocol.

Table 2 - Stability of Lyophilized Formulation containing 250 mg Lamotrigine per vial.

Test	Appearance	pH	Assay	Related Substances			Moisture Content
			lamotrigine	g	individual other	Total	
Specifications	a	Report Results	90.0 to 110.0% I.S.	≤0.5% w/w	≤0.5% w/w	≤1.0% w/w	Report Results
Initial	b,e	3.6	101.7	<0.1	<0.1	<0.1	0.5
	b,f	3.6	101.1	<0.1	<0.1	<0.1	0.4
	b,g	3.6	101.1	<0.1	<0.1	<0.1	0.4
At Storage	b	3.5					
Reconstitution Study							
1 day	NC	3.5	102.4	<0.1	<0.1	<0.1	-
3 day	NC	3.4	103.2	<0.1	<0.1	<0.1	-
25°C/60% RH							
1 month	NC	3.5	102.5	<0.1	<0.1	<0.1	-
3 months	c	3.6	102.8	<0.1	<0.1	<0.1	-
	b,d	3.4	102.8	<0.1	-	-	-
	b,d	3.4	-	-	-	-	-
6 months	b,d	3.4	-	-	-	-	-
	NC	3.5	100.4	<0.1	<0.1	<0.1	0.5
40°C/75% RH							
1 month	NC	3.6	104.5	<0.1	<0.1	<0.1	0.5
3 months	NC	3.4	103.2	<0.1	<0.1	<0.1	0.7
6 months	NC	3.5	102.6	<0.1	<0.1	<0.1	0.6
30°C/60% RH							
6 months	NC	3.4	102.8	<0.1	<0.1	<0.1	0.5

a A white to off-white freeze-dried powder; reconstituted: A clear colorless solution, with no particulate matter, swirl, or odor.

b A white to off-white freeze-dried powder; Reconstituted: clear colorless solution, no particulate matter, no swirl, no odor.

c Drug product once reconstituted was white, product had precipitated out, was moderately hazy and cloudy.

d Triplicate resample performed to verify the original data value for this test period.

e For all data on this line, testing was performed on sampled material from the beginning of the manufacturing run.

f For all data on this line, testing was performed on sampled material from the middle of the manufacturing run.

g 3-Amino-5-keto-6-(2,3-dichlorophenyl)-1,2,4-triazine.

**Table 3 - Chemical Assay of Reconstituted Solution containing 20 mg Lamotrigine per mL**

Storage Conditions	Lamotrigine (percent label strength)	b (percent)
Specifications	90-110	0-0.5
Initial (reconstituted)	101.3	<0.1
1 day, 30°C <sup>a</sup>	99.5	<0.1
3 days, 30°C <sup>a</sup>	100.1	<0.2

<sup>a</sup> Mean of three samples. Assay by High Performance Liquid Chromatography (HPLC) according to the Analytical Standard.

<sup>b</sup> 3-Amino-5-keto-6-(2,3-dichlorophenyl)-1,2,4-triazine.

**Table 4- Particulate Analysis of Reconstituted Solution containing 20 mg Lamotrigine per mL**

Storage Conditions	HIAC Royco Analysis-Particles per Container		
	> 5µm 0-100,000	>10µm 0-10,000	>25µm 0-1,000
Initial <sup>b</sup>	593	142	5
1 day	673	163	3
3 day	305	28	0

<sup>a</sup> Mean of five samples.

<sup>b</sup> Average of three separate determinations of five samples.

**Claims**

- 5 1. A lyophilized formulation containing lamotrigine mesylate present in an amount of 100 to 1000mg, calculated as the free base.
2. A formulation according to claim 1, wherein lamotrigine mesylate is present in an amount of 250 to 1000mg, calculated as the free base.
- 10 3. A formulation according to claim 2, wherein lamotrigine mesylate is present in an amount of substantially 250 mg, calculated as the free base.
- 15 4. A lyophilized formulation of lamotrigine having been prepared by lyophilizing a substantially frozen sterile aqueous solution of lamotrigine mesylate in which the pH is from 2.5 to 4.
5. A formulation according to claim 4, wherein the concentration of lamotrigine mesylate prior to lyophilization, calculated as the free base, is from 1 to 60 mg/ml.
- 20 6. A formulation according to claim 5, wherein the concentration of lamotrigine mesylate prior to lyophilization is from 20 to 30 mg/ml, calculated as the free base.
- 25 7. A formulation according to any of claims 4 to 6, wherein the pH of the aqueous solution is from 2.8 to 3.5.
8. A formulation according to claim 7, wherein the pH of the aqueous solution is from 3.3 to 3.5.

9. A formulation according to any of claims 4 to 8, wherein the solution is wholly or substantially aqueous.

5 10. A formulation according to any of claims 1 to 9, which further comprises at least one bulking agent.

11. A formulation according to claim 10, wherein the bulking agent is selected from the group consisting of mannitol, dextrose, lactose, sucrose, sorbitol and glycine.

10 12. A formulation according to claim 11, wherein the agent is mannitol.

13. A formulation according to any of claims 10 to 12, wherein the bulking agent is present in an amount of about 192 to 470mg.

15 14. A formulation according to any of claims 1 to 13, wherein lamotrigine mesylate is formed from lamotrigine free base and methanesulphonic acid, the free base and acid being present in a substantially equimolar ratio.

20 15. An injectable formulation containing lamotrigine mesylate, wherein the concentration of lamotrigine mesylate is in the range of 1 to 60 mg/ml, calculated as the free base.

25 16. An injectable formulation containing lamotrigine mesylate, wherein the concentration of lamotrigine mesylate is in the range of 1 to 60 mg/ml, calculated as the free-base, which formulation is prepared by re-constitution of a lyophilized formulation according to any of claims 1 to 14 with a sterile carrier suitable for intravenous administration.

30 17. A formulation according to claim 15 or 16, wherein the concentration of lamotrigine mesylate is in the range of 1 to 50 mg/ml, calculated as the free base.

18. A formulation according to claim 17, wherein the concentration of lamotrigine mesylate is in the range of 1 to 20 mg/ml, calculated as the free base.

5

19. A formulation according to claim 18, wherein the concentration of lamotrigine mesylate is in the range of 1 to 15 mg/ml, calculated as the free base.

10

20. A formulation according to claim 18, wherein the concentration of lamotrigine mesylate is substantially 20mg/ml, calculated as the free base.

21. A formulation according to any of claims 15 to 20, having a pH in the range of 3.4 to 4.

15

22. A formulation according to any of claims 15 to 21, which is prepared by re-constituting a lyophilized formulation according to any of claims 1 to 14 with sterile water for injection or 5% dextrose solution.

20

23. A formulation according to any of claims 15 to 22, which further comprises at least one bulking agent.

24. A formulation according to claim 23, wherein the bulking agent is selected from the group consisting of mannitol, dextrose, lactose, sucrose, sorbitol and glycine.

25

25. A formulation according to claim 24, wherein the bulking agent is mannitol.

26. A formulation according to any of claims 23 to 25, wherein the concentration of the bulking agent is in the range of 12 to 47 mg/ml.

30

27. A formulation according to any of claims 16 to 26, wherein lamotrigine mesylate is formed from lamotrigine free base and methanesulphonic acid, the free base and acid being present in a substantially equimolar ratio.

5 28. Use of a lyophilized formulation according to any of claims 1 to 14, in the manufacture of an injectable formulation containing lamotrigine.

29. Use according to claim 28, wherein the injectable formulation is as defined in any of claims 15 to 27.

10

30. A method of treating a patient with epilepsy, which method comprises intravenously administering to the patient an injectable formulation according to any of claims 15 to 27.

15

31. A process of preparing a lyophilized formulation of lamotrigine, which process comprises lyophilizing a substantially frozen sterile aqueous solution of lamotrigine mesylate in which the pH is from 2.5 to 4.

20

32. A process according to claim 31, wherein the concentration of lamotrigine mesylate prior to lyophilization, calculated as the free base, is from 1 to 60 mg/ml.

25

33. A process according to claim 32, wherein the concentration of lamotrigine mesylate, prior to lyophilization, is from 20 to 30 mg/ml, calculated as the free base.

34. A process according to any of claims 31 to 33, wherein the pH of the aqueous solution is from 2.8 to 3.5.

30

35. A process according to claim 34, wherein the pH of the aqueous solution is from 3.3 to 3.5.

35

36. A process according to any of claims 31 to 35, wherein at least one bulking agent is included in the aqueous solution prior to lyophilization.

37. A process according to claim 36, wherein the agent is selected from the group consisting of mannitol, dextrose, lactose, sucrose, sorbitol and glycine.

5 38. A process according to claim 37, wherein the bulking agent is mannitol.

10 39. A process of preparing an injectable formulation according to any of claims 15 to 27, which process comprises reconstituting a lyophilized formulation according to any of claims 1 to 14, with a sterile carrier suitable for intravenous administration.

40. A lyophilized formulation comprising 250.0mg of lamotrigine, 377.8mg of mannitol and 93.75mg of methanesulphonic acid.

15

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 96/02759

A. CLASSIFICATION OF SUBJECT MATTER  
 IPC 6 A61K31/53 A61K9/14 A61K9/19

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO,A,94 20108 (RHONE-POULENC RORER S.A.,FR) 15 September 1994 see claims see examples see page 2, line 13 see page 3, line 16 - line 18 ---	1-40
A	WO,A,94 13296 (RHONE-POULENC RORER S.A.,FR) 23 June 1994 see claims see examples see page 3, line 16 see page 4, line 20 - line 22 ---	1-40
Y	EP,A,0 247 892 (THE WELLCOME FOUNDATION LIMITED,UK) 2 December 1987 cited in the application see the whole document ---	1-40
-/--		

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

## \* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- "&" document member of the same patent family

Date of the actual completion of the international search

10 October 1996

Date of mailing of the international search report

22.10.96

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
 NL - 2280 HV Rijswijk  
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
 Fax (+31-70) 340-3016

Authorized officer

Scarponi, U

## INTERNATIONAL SEARCH REPORT

Inter      nal Application No  
PCT/EP 96/02759

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO,A,95 05179 (THE WELLCOME FOUNDATION LIMITED,UK) 23 February 1995 see claims see page 2, line 9 - line 10 see page 3, line 5 - line 11 see page 6, line 1 - line 10 -----	1-40

# INTERNATIONAL SEARCH REPORT

International application No.

PCT/EP 96/ 02759

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:  
Remark: Although claim 30 is directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 96/02759

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO-A-9420108	15-09-94	FR-A- 2702148	09-09-94
		AU-A- 6143794	26-09-94
		AU-A- 6143894	26-09-94
		AU-A- 6143994	26-09-94
		CA-A- 2154571	15-09-94
		CA-A- 2154572	15-09-94
		CA-A- 2154573	15-09-94
		CZ-A- 9502259	13-12-95
		CZ-A- 9502260	13-12-95
		CZ-A- 9502261	13-12-95
		EP-A- 0687176	20-12-95
		EP-A- 0687179	20-12-95
		EP-A- 0687177	20-12-95
		WO-A- 9420103	15-09-94
		WO-A- 9420110	15-09-94
		HU-A- 73434	29-07-96
		HU-A- 73433	29-07-96
		JP-T- 8507507	13-08-96
		JP-T- 8507508	13-08-96
		JP-T- 8507509	13-08-96
		NO-A- 953370	28-08-95
		NO-A- 953371	28-08-95
		NO-A- 953372	28-08-95
		PL-A- 310474	11-12-95
		PL-A- 310475	11-12-95
		PL-A- 310476	11-12-95
		ZA-A- 9401525	09-11-94
		ZA-A- 9401530	06-10-94
WO-A-9413296	23-06-94	FR-A- 2699077	17-06-94
		AU-A- 5653994	04-07-94
		AU-A- 5654094	04-07-94
		AU-A- 5702094	04-07-94
		CA-A- 2151601	23-06-94
		CA-A- 2151603	23-06-94
		CA-A- 2151604	23-06-94
		CZ-A- 9501545	15-11-95
		CZ-A- 9501546	15-11-95
		CZ-A- 9501547	15-11-95
		EP-A- 0674520	04-10-95

## INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 96/02759

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO-A-9413296		EP-A- 0674512	04-10-95
		EP-A- 0674518	04-10-95
		WO-A- 9413298	23-06-94
		WO-A- 9413288	23-06-94
		FR-A- 2699079	17-06-94
		FR-A- 2699078	17-06-94
		HU-A- 71814	28-02-96
		HU-A- 71839	28-02-96
		HU-A- 71812	28-02-96
		JP-T- 8504428	14-05-96
		JP-T- 8504429	14-05-96
		JP-T- 8504430	14-05-96
		NO-A- 952228	06-06-95
		NO-A- 952229	06-06-95
		NO-A- 952230	06-06-95
		PL-A- 309346	02-10-95
		PL-A- 309347	02-10-95
		PL-A- 309348	02-10-95
		ZA-A- 9309399	22-08-94
		ZA-A- 9309400	19-08-94
		ZA-A- 9309401	19-08-94
EP-A-247892	02-12-87	AU-B- 597982	14-06-90
		AU-A- 7368487	03-12-87
		CA-A- 1286670	23-07-91
		FI-C- 90770	25-03-94
		IE-B- 60626	27-07-94
		JP-B- 7051571	05-06-95
		JP-A- 62289570	16-12-87
		US-A- 4847249	11-07-89
WO-A-9505179	23-02-95	AU-A- 7389794	14-03-95